PhytoFoundry produces high-value cosmetic bioactives using programmable plant cell lines — 100× the yield of the source plant, with batch-to-batch consistency and zero dependence on harvest, weather, or geopolitics.
The bioactives that drive anti-ageing efficacy — bakuchiol, glabridin, rare plant peptides — are trapped inside slow-growing, geographically concentrated plants. The industry has no reliable, scalable alternative.
We engineer proprietary plant cell lines that produce target bioactives continuously — no soil, no seasons, no geographic constraints. Our core expertise is cell line development: the foundation of every product, and a standalone service for partners.
Recurring B2B revenue from cosmetic brands purchasing standardised, specification-locked bioactive ingredients. Lead product: PhytoDerm-1.
PhytoFoundry's core expertise — screening, selecting, and optimising high-performing plant cell lines — offered as a contract service to pharmaceutical, food, and cosmetic ingredient companies.
Proprietary elite cell lines and bioprocess protocols licensable to partners seeking manufacturing rights in specific territories or markets.
Our platform applies established plant cell culture science — refined over decades in pharmaceutical and food ingredient production — to the high-margin cosmetic bioactives market.
Proprietary screening and selection methodology identifies high-producing cell lines with stable, reproducible bioactive profiles. Each ECL is the foundation of a defensible IP position.
Targeted elicitation protocols channel metabolic flux toward the desired bioactive, dramatically increasing yield while suppressing co-metabolites including allergenic furanocoumarins.
The same platform technology that produces PhytoDerm-1 (bakuchiol-enriched active) is applicable across the cosmetic bioactive pipeline — glabridin, edelweiss peptides, and beyond.
Peer-reviewed Life Cycle Assessment published in Sustainability (2024) validates the environmental advantage of cell culture over conventional botanical extraction at scale.
HPLC-standardised at defined bioactive content. Specification sheets, safety data, and regulatory documentation aligned with EU and US cosmetic ingredient requirements.
Technology transfer to specialist contract manufacturing organisations enables commercial scale without capital-intensive infrastructure — preserving equity for R&D and commercial growth.
PhytoFoundry is currently raising a bridge round ahead of a £750k pre-seed close in Q3/Q4 2026. Register below to request access to the investor data room.
Your details will be reviewed within 48 hours. Approved investors will receive a data room link by email. Access is granted at our discretion to qualified investors. This does not constitute an offer to invest.
Thank you. We will review your details and be in touch within 48 hours at the email provided.